Literature DB >> 23656576

Spinal and bulbar muscular atrophy: pathogenesis and clinical management.

C Grunseich1, C Rinaldi, K H Fischbeck.   

Abstract

Spinal and bulbar muscular atrophy, or Kennedy's disease, is an X-linked motor neuron disease caused by polyglutamine repeat expansion in the androgen receptor. The disease is characterised by weakness, atrophy and fasciculations in the limb and bulbar muscles. Affected males may have signs of androgen insensitivity, such as gynaecomastia and reduced fertility. Neurophysiological studies are typically consistent with diffuse denervation atrophy, and serum creatine kinase is usually elevated 2-5 times above normal. Progression of the disease is slow, and the focus of spinal and bulbar muscular atrophy (SBMA) management is to prevent complications. Published 2013. This article is a US Government work and is in the public domain in the USA.

Entities:  

Keywords:  Kennedy's disease; craniofacial; genetics; motor neuron disease; spinal and bulbar muscular atrophy; weakness

Mesh:

Year:  2013        PMID: 23656576      PMCID: PMC4284073          DOI: 10.1111/odi.12121

Source DB:  PubMed          Journal:  Oral Dis        ISSN: 1354-523X            Impact factor:   3.511


  34 in total

1.  Native functions of the androgen receptor are essential to pathogenesis in a Drosophila model of spinobulbar muscular atrophy.

Authors:  Natalia B Nedelsky; Maria Pennuto; Rebecca B Smith; Isabella Palazzolo; Jennifer Moore; Zhiping Nie; Geoffrey Neale; J Paul Taylor
Journal:  Neuron       Date:  2010-09-23       Impact factor: 17.173

2.  CREB-binding protein sequestration by expanded polyglutamine.

Authors:  A McCampbell; J P Taylor; A A Taye; J Robitschek; M Li; J Walcott; D Merry; Y Chai; H Paulson; G Sobue; K H Fischbeck
Journal:  Hum Mol Genet       Date:  2000-09-01       Impact factor: 6.150

Review 3.  Glutamine repeats and neurodegeneration.

Authors:  H Y Zoghbi; H T Orr
Journal:  Annu Rev Neurosci       Date:  2000       Impact factor: 12.449

4.  Efficacy and safety of dutasteride in patients with spinal and bulbar muscular atrophy: a randomised placebo-controlled trial.

Authors:  Lindsay E Fernández-Rhodes; Angela D Kokkinis; Michelle J White; Charlotte A Watts; Sungyoung Auh; Neal O Jeffries; Joseph A Shrader; Tanya J Lehky; Li Li; Jennifer E Ryder; Ellen W Levy; Beth I Solomon; Michael O Harris-Love; Alison La Pean; Alice B Schindler; Cheunju Chen; Nicholas A Di Prospero; Kenneth H Fischbeck
Journal:  Lancet Neurol       Date:  2011-01-06       Impact factor: 44.182

5.  Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study): a multicentre, randomised, double-blind, placebo-controlled trial.

Authors:  Masahisa Katsuno; Haruhiko Banno; Keisuke Suzuki; Yu Takeuchi; Motoshi Kawashima; Ichiro Yabe; Hidenao Sasaki; Masashi Aoki; Mitsuya Morita; Imaharu Nakano; Kazuaki Kanai; Shoichi Ito; Kinya Ishikawa; Hidehiro Mizusawa; Tomotaka Yamamoto; Shoji Tsuji; Kazuko Hasegawa; Takayoshi Shimohata; Masatoyo Nishizawa; Hiroaki Miyajima; Fumio Kanda; Yasuhiro Watanabe; Kenji Nakashima; Akira Tsujino; Taro Yamashita; Makoto Uchino; Yasushi Fujimoto; Fumiaki Tanaka; Gen Sobue
Journal:  Lancet Neurol       Date:  2010-08-04       Impact factor: 44.182

6.  Tremor in X-linked recessive spinal and bulbar muscular atrophy (Kennedy's disease).

Authors:  Francisco A Dias; Renato P Munhoz; Salmo Raskin; Lineu César Werneck; Hélio A G Teive
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

7.  Clinical features of spinal and bulbar muscular atrophy.

Authors:  Lindsay E Rhodes; Brandi K Freeman; Sungyoung Auh; Angela D Kokkinis; Alison La Pean; Cheunju Chen; Tanya J Lehky; Joseph A Shrader; Ellen W Levy; Michael Harris-Love; Nicholas A Di Prospero; Kenneth H Fischbeck
Journal:  Brain       Date:  2009-12       Impact factor: 13.501

8.  Standard and modified statistical MUNE evaluations in spinal-bulbar muscular atrophy.

Authors:  Tanya J Lehky; Cheun Ju Chen; Nicholas A di Prospero; Lindsay E Rhodes; Kenneth Fischbeck; Mary Kay Floeter
Journal:  Muscle Nerve       Date:  2009-11       Impact factor: 3.217

9.  Phase 2 trial of leuprorelin in patients with spinal and bulbar muscular atrophy.

Authors:  Haruhiko Banno; Masahisa Katsuno; Keisuke Suzuki; Yu Takeuchi; Motoshi Kawashima; Noriaki Suga; Motoko Takamori; Mizuki Ito; Tomohiko Nakamura; Koji Matsuo; Shinichi Yamada; Yumiko Oki; Hiroaki Adachi; Makoto Minamiyama; Masahiro Waza; Naoki Atsuta; Hirohisa Watanabe; Yasushi Fujimoto; Tsutomu Nakashima; Fumiaki Tanaka; Manabu Doyu; Gen Sobue
Journal:  Ann Neurol       Date:  2009-02       Impact factor: 10.422

10.  Identifying polyglutamine protein species in situ that best predict neurodegeneration.

Authors:  Jason Miller; Montserrat Arrasate; Elizabeth Brooks; Clare Peters Libeu; Justin Legleiter; Danny Hatters; Jessica Curtis; Kenneth Cheung; Preethi Krishnan; Siddhartha Mitra; Kartika Widjaja; Benjamin A Shaby; Gregor P Lotz; Yvonne Newhouse; Emily J Mitchell; Alex Osmand; Michelle Gray; Vanitha Thulasiramin; Frédéric Saudou; Mark Segal; X William Yang; Eliezer Masliah; Leslie M Thompson; Paul J Muchowski; Karl H Weisgraber; Steven Finkbeiner
Journal:  Nat Chem Biol       Date:  2011-10-30       Impact factor: 15.040

View more
  21 in total

Review 1.  Onset Manifestations of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease).

Authors:  Josef Finsterer; Gianni Soraru
Journal:  J Mol Neurosci       Date:  2015-10-19       Impact factor: 3.444

2.  Brain MRI shows white matter sparing in Kennedy's disease and slow-progressing lower motor neuron disease.

Authors:  Edoardo G Spinelli; Federica Agosta; Pilar M Ferraro; Giorgia Querin; Nilo Riva; Cinzia Bertolin; Ilaria Martinelli; Christian Lunetta; Andrea Fontana; Gianni Sorarù; Massimo Filippi
Journal:  Hum Brain Mapp       Date:  2019-03-28       Impact factor: 5.038

Review 3.  Spinal and Bulbar Muscular Atrophy.

Authors:  Christopher Grunseich; Kenneth H Fischbeck
Journal:  Neurol Clin       Date:  2015-09-08       Impact factor: 3.806

4.  Early onset and novel features in a spinal and bulbar muscular atrophy patient with a 68 CAG repeat.

Authors:  Christopher Grunseich; Ilona R Kats; Laura C Bott; Carlo Rinaldi; Angela Kokkinis; Derrick Fox; Ke-Lian Chen; Alice B Schindler; Ami K Mankodi; Joseph A Shrader; Daniel P Schwartz; Tanya J Lehky; Chia-Ying Liu; Kenneth H Fischbeck
Journal:  Neuromuscul Disord       Date:  2014-07-03       Impact factor: 4.296

5.  Selective vulnerability in neuronal populations in nmd/SMARD1 mice.

Authors:  Eric Villalón; Monir Shababi; Rachel Kline; Zachary C Lorson; Kyra M Florea; Christian L Lorson
Journal:  Hum Mol Genet       Date:  2018-02-15       Impact factor: 6.150

6.  Linking epigenetic dysregulation, mitochondrial impairment, and metabolic dysfunction in SBMA motor neurons.

Authors:  Naemeh Pourshafie; Ester Masati; Eric Bunker; Alec R Nickolls; Parisorn Thepmankorn; Kory Johnson; Xia Feng; Tyler Ekins; Christopher Grunseich; Kenneth H Fischbeck
Journal:  JCI Insight       Date:  2020-07-09

7.  Theory of mind, empathy and neuropsychological functioning in X-linked spinal and bulbar muscular atrophy: a controlled study of 20 patients.

Authors:  Elisa Di Rosa; Gianni Sorarù; Johann Roland Kleinbub; Vincenzo Calvo; Antonino Vallesi; Giorgia Querin; Sonia Marcato; Irene Grasso; Arianna Palmieri
Journal:  J Neurol       Date:  2014-11-20       Impact factor: 4.849

8.  Muscle fiber-type selective propensity to pathology in the nmd mouse model of SMARD1.

Authors:  Eric Villalón; Naomi N Lee; Jose Marquez; Christian L Lorson
Journal:  Biochem Biophys Res Commun       Date:  2019-06-28       Impact factor: 3.575

9.  Gene therapy with AR isoform 2 rescues spinal and bulbar muscular atrophy phenotype by modulating AR transcriptional activity.

Authors:  Wooi F Lim; Mitra Forouhan; Thomas C Roberts; Jesse Dabney; Ruth Ellerington; Alfina A Speciale; Raquel Manzano; Maria Lieto; Gavinda Sangha; Subhashis Banerjee; Mariana Conceição; Lara Cravo; Annabelle Biscans; Loïc Roux; Naemeh Pourshafie; Christopher Grunseich; Stephanie Duguez; Anastasia Khvorova; Maria Pennuto; Constanza J Cortes; Albert R La Spada; Kenneth H Fischbeck; Matthew J A Wood; Carlo Rinaldi
Journal:  Sci Adv       Date:  2021-08-20       Impact factor: 14.136

Review 10.  The Role of the Protein Quality Control System in SBMA.

Authors:  Paola Rusmini; Valeria Crippa; Riccardo Cristofani; Carlo Rinaldi; Maria Elena Cicardi; Mariarita Galbiati; Serena Carra; Bilal Malik; Linda Greensmith; Angelo Poletti
Journal:  J Mol Neurosci       Date:  2015-11-14       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.